GSK's depemokimab under review in China and Japan for asthma, CRSwNP
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...
GSK announces new drug applications accepted for review in China, Japan
GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...
pharmaphorum2d
Stopwatch starts on reviews of GSK's long-acting asthma drug
Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...
Hosted on MSN23h
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...
Pharmabiz1d
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...
GSK applications for sinus disease treatment accepted for review
(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...
Sharecast5mon
GSK upbeat on Zantac litigation development, Japan approvals
In a separate development, GSK announced that its monoclonal antibody, ‘Nucala’, or mepolizumab, had been approved by Japan's Ministry of Health, Labour and Welfare (MHLW) for treating adults ...
pharmaphorum5y
Astellas gets nod in Japan for roxadustat, ahead of GSK rival
Roxadustat is the first drug in the hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor class to be approved in Japan, beating its closest rival – daprodustat from GlaxoSmithKline ...